CompaniesGala Therapeutics

Gala Therapeutics

defunct
About

Defunct Company

Areas of Focus

Categories

Rebranded/RenamedBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (8)
View all

Total Trials

8

As Lead Sponsor

8

As Collaborator

0

Total Enrollment

924

By Phase

PHASE3: 1NA: 6

By Status

RECRUITING: 3COMPLETED: 3ACTIVE_NOT_RECRUITING: 1UNKNOWN: 1
Clinical Trials Pipeline8 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
NCT03107494
NCT03385616
NCT03631472
NCT04182841
NCT04677465
NCT05880680
NCT05831202
Hover over trial bars to see details

Recent Trials

NCT05831202Lead Sponsor
SEAL™IT: Saccular Endovascular Aneurysm Lattice System Interventional Pivotal Trial
PHASE3Recruiting
279 participants
Started: Aug 6, 2024 · Completed: Sep 10, 2030
NCT05880680Lead Sponsor
SEAL™ME: Saccular Endovascular Aneurysm Lattice System Multicenter Enrollment Global Registry
N/ARecruiting
200 participants
Started: Oct 9, 2023 · Completed: Jun 15, 2030
NCT05686733Lead Sponsor
Pre-SEAL™IT: Saccular Endovascular Aneurysm Lattice System First In Human Interventional Trial
NACompleted
26 participants
Started: Jan 26, 2022 · Completed: Feb 17, 2024
NCT04677465Lead Sponsor
Clinical Study of the RheOx Bronchial Rheoplasty System in Treating the Symptoms of Chronic Bronchitis
NAActive, not recruiting
270 participants
Started: Apr 7, 2021 · Completed: Oct 31, 2025
NCT04182841Lead Sponsor
RheOx Registry Study in Europe
NARecruiting
100 participants
Started: Jan 9, 2020 · Completed: Dec 15, 2025
View all 8 trials →
Funding History (5)
D
Sep 11, 2025
Filing
D
Mar 22, 2022
Filing
D
Mar 9, 2022
Filing
D/A
Nov 18, 2019
Filing
D
Mar 13, 2019
Filing